Skip to main content

Acute Stroke

Neurology
8
Pipeline Programs
19
Companies
20
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
2
1
0
2
0
Early DiscoveryClinical DevelopmentMarket

Neurology is a $26.9B market dominated by a single blockbuster anticoagulant (ELIQUIS), representing a mature but consolidating therapeutic area.

$26.9B marketMature→ Stable30 products15 companies

Key Trends

  • Extreme market concentration: 68% of spending driven by one FXa inhibitor product
  • Psychiatric and migraine therapies emerging as secondary growth drivers
  • High clinical trial activity (8,279 trials) signals continued pipeline development

Career Verdict

Neurology offers solid career stability with good hiring demand, but limited upside growth—best suited for professionals seeking established market positions rather than emerging-area innovation.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1ELIQUISStable
$18.3B
Bristol Myers Squibb·Launch15.0yr
$1.8B
#3BRILINTAStable
$692M
AstraZeneca·Peak10.2yr
#4NUPLAZIDStable
$596M
$530M
Johnson & Johnson·Peak15.6yr

Drug Class Breakdown

FXa Inhibitors (anticoagulant)
$18.3B(68%)

market-defining single product

Dopamine/Serotonin Antagonists (psychiatric)
$2.4B(9%)

stable mature class

P2Y12 Receptor Antagonists (antiplatelet)
$692M(3%)

niche but stable

5-HT2A Inverse Agonists (psychiatric)
$596M(2%)

specialty indication focus

CGRP Receptor Antagonists (migraine)
$931M(3%)

emerging growth segment

Immunomodulators (MS)
$747M(3%)

stable with LOE risk

Other mechanisms
$2.6B(10%)

diverse small products

Career Outlook

Stable

Neurology represents a mature, cash-generative market with limited growth tailwinds but strong hiring stability. The dominance of ELIQUIS creates a bifurcated career landscape: high-opportunity positions in emerging segments (CGRP antagonists, psychiatric therapeutics) and commoditized roles in anticoagulant franchises. Job availability is solid but growth expectations should be tempered relative to oncology or immunology.

Breaking In

Entry-level professionals should target clinical operations or commercial support roles at J&J, AstraZeneca, or Sanofi to build domain expertise in neurology disease states and competitive dynamics.

For Experienced Professionals

Experienced professionals should prioritize emerging mechanism roles (CGRP, tau-targeting programs) or pivot to medtech/neurotech (Stryker, Medtronic) to capture higher growth and salary potential than traditional pharma incumbents.

In-Demand Skills

Medical Science Liaisons (MSL) for specialist engagementClinical trial operations expertisePsychiatric/neurodegenerative disease educationRegulatory affairs (given patent cliff activity)Commercial strategy around branded/generic transitions

Best For

Medical Science LiaisonCommercial Brand Manager (anticoagulant/psychiatric franchises)Clinical Operations ManagerRegulatory Affairs SpecialistClinical Development Manager (CGRP/immunomodulator pipelines)

Hiring Landscape

$100K-$199K

Neurology shows moderate but distributed hiring across pharma and medtech employers, with 4,186 total jobs listed. Commercial functions lead (947 roles, $169K avg), followed by clinical operations (467 roles, $132K avg), indicating bias toward commercialization over R&D. Takeda leads external hiring (762 jobs) with strong representation in contract research and CRO spaces.

4,186
Open Roles
5
Companies Hiring
5
Departments

Top Hiring Companies

762Growing
434Stable
302Stable

By Department

Commercial(23%)
$169K
Clinical Operations(11%)
$132K
Engineering(8%)
$199K
IT(4%)
$100K
Manufacturing(3%)
$170K

Commercial and clinical operations roles dominate, offering stable mid-career positions; engineering roles command premium salaries ($199K), suggesting strong device/neurotech hiring pockets.

Competitive Landscape

19 companies ranked by most advanced pipeline stage

Medtronic
MedtronicNJ - Phillipsburg
2 programs
1
Solitaire FR devicePhase 31 trial
IMPROVE Stroke Care- Developing and Optimizing Regional Systems of Stroke CareN/A1 trial
Active Trials
NCT04242784Completed21,646Est. Apr 2021
NCT01692379Terminated206Est. Dec 2015
Ferrer
FerrerSpain - Barcelona
1 program
1
CiticolinePhase 31 trial
Active Trials
NCT00331890Terminated2,298Est. Mar 2012
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
1
Stroke Emergency Mobile UnitPhase 21 trial
Active Trials
NCT01382862Completed614Est. May 2013
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
4 programs
1
1
Magnesium SulfatePhase 1/21 trial
NeuroFloPhase 11 trial
Tight control of end-tidal CO2 levelsN/A1 trial
endovascular samplingN/A1 trial
Active Trials
NCT03737786Recruiting90Est. Dec 2026
NCT01502748Terminated2Est. Feb 2013
NCT00653536Withdrawn0Est. Jan 2013
+1 more trials
International Stem Cell
1 program
1
DonepezilPhase 1/21 trial
Active Trials
NCT01442766Withdrawn0Est. May 2014
Stryker
StrykerCA - San Jose
1 program
1
Endovascular TreatmentPhase 11 trial
Active Trials
NCT02618031Completed57Est. Dec 2018
Biocorp
BiocorpFrance - Issoire
1 program
1
UMSC01Phase 11 trial
Active Trials
NCT04434768Active Not Recruiting10Est. Feb 2026
BrainQ
BrainQIsrael - Jerusalem
1 program
BQN/A1 trial
Active Trials
NCT04039178Terminated28Est. Mar 2020
Anagram Therapeutics
Anagram TherapeuticsMA - Framingham
1 program
BraiN20N/A
Innovation Pharmaceuticals
1 program
BraiN20N/A1 trial
Active Trials
NCT06149754Unknown65Est. May 2024
Daiichi Sankyo
Daiichi SankyoChina - Shanghai
1 program
IMPROVE Stroke Care- Developing and Optimizing Regional Systems of Stroke CareN/A
Chiesi
ChiesiBrazil - Santana de Parnaíba
1 program
IMPROVE Stroke Care- Developing and Optimizing Regional Systems of Stroke CareN/A
Acandis
AcandisGermany - Pforzheim
1 program
Mechanical ThrombectomyN/A1 trial
Active Trials
NCT04479020Completed134Est. May 2024
Neurosteer
NeurosteerIsrael - Tel Aviv
1 program
Neurosteer EEG recorderN/A1 trial
Active Trials
NCT05524415Withdrawn0Est. Dec 2023
MIVI Neuroscience
MIVI NeuroscienceMN - Eden Prairie
1 program
Q Revascularization SystemN/A1 trial
Active Trials
NCT04437862Completed121Est. Aug 2023
Sparrow Pharmaceuticals
1 program
SCMN/A1 trial
Active Trials
NCT02653170Completed320Est. Nov 2017
Genentech
GenentechCA - Oceanside
1 program
IV rt-PAPHASE_21 trial
Active Trials
NCT01282242Completed88Est. May 2016
Pharmazz
PharmazzIndia - Greater Noida
1 program
Normal Saline along with standard treatmentPHASE_21 trial
Active Trials
NCT04046484Completed40Est. Jun 2019
DiaMedica Therapeutics
DiaMedica TherapeuticsMINNEAPOLIS, MN
1 program
Recombinant human tissue kallikreinPHASE_2_31 trial
Active Trials
NCT05065216Recruiting728Est. Dec 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
MedtronicSolitaire FR device
FerrerCiticoline
DiaMedica TherapeuticsRecombinant human tissue kallikrein
PharmazzNormal Saline along with standard treatment
UNION therapeuticsStroke Emergency Mobile Unit
GenentechIV rt-PA
Angeles TherapeuticsMagnesium Sulfate
International Stem CellDonepezil
BiocorpUMSC01
StrykerEndovascular Treatment
Angeles TherapeuticsNeuroFlo
Innovation PharmaceuticalsBraiN20
NeurosteerNeurosteer EEG recorder
MIVI NeuroscienceQ Revascularization System
AcandisMechanical Thrombectomy

Showing 15 of 20 trials with date data

Clinical Trials (20)

Total enrollment: 26,451 patients across 20 trials

NCT01692379MedtronicSolitaire FR device

Endovascular Revascularization With Solitaire Device Versus Best Medical Therapy in Anterior Circulation Stroke Within 8 Hours

Start: Nov 2012Est. completion: Dec 2015206 patients
Phase 3Terminated

ICTUS Study: International Citicoline Trial on Acute Stroke

Start: Oct 2006Est. completion: Mar 20122,298 patients
Phase 3Terminated
NCT05065216DiaMedica TherapeuticsRecombinant human tissue kallikrein

Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

Start: Nov 2021Est. completion: Dec 2026728 patients
Phase 2/3Recruiting
NCT04046484PharmazzNormal Saline along with standard treatment

PMZ-1620 (Sovateltide) in Acute Ischemic Stroke Patients

Start: Jan 2018Est. completion: Jun 201940 patients
Phase 2Completed
NCT01382862UNION therapeuticsStroke Emergency Mobile Unit

PHANTOM-S: The Pre-Hospital Acute Neurological Therapy and Optimization of Medical Care in Stroke Patients - Study

Start: May 2011Est. completion: May 2013614 patients
Phase 2Completed

A Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients

Start: Jan 2011Est. completion: May 201688 patients
Phase 2Completed

Intra-arterial Magnesium Administration for Acute Stroke

Start: Mar 2012Est. completion: May 20164 patients
Phase 1/2Terminated

Donepezil Trial for Motor Recovery in Acute Stroke

Start: Nov 2011Est. completion: May 20140
Phase 1/2Withdrawn

Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Ischemic Stroke

Start: Dec 2020Est. completion: Feb 202610 patients
Phase 1Active Not Recruiting
NCT02618031StrykerEndovascular Treatment

The Capillary Index Score Trial

Start: Mar 2016Est. completion: Dec 201857 patients
Phase 1Completed

A Study to Evaluate the Effects of the Neuroflo Device in People Who Have Had a Stroke

Start: Mar 2008Est. completion: Jan 20130
Phase 1Withdrawn

BraiN20® Monitoring in Acute Stroke Undergoing Thrombectomy

Start: Sep 2023Est. completion: May 202465 patients
N/AUnknown
NCT05524415NeurosteerNeurosteer EEG recorder

Evaluation of Neurosteer System in Stroke Patients

Start: Jan 2023Est. completion: Dec 20230
N/AWithdrawn
NCT04437862MIVI NeuroscienceQ Revascularization System

A Study to Evaluate the Q Revascularization System for Neurointervention in Acute Ischemic Stroke

Start: Oct 2020Est. completion: Aug 2023121 patients
N/ACompleted
NCT04479020AcandisMechanical Thrombectomy

REcanalization of Distal Cerebral Vessels in Acute Stroke Using ApeRio®

Start: Jul 2020Est. completion: May 2024134 patients
N/ACompleted
NCT03737786Angeles TherapeuticsTight control of end-tidal CO2 levels

SEACOAST 1- SEdAtion With COllAteral Support in Endovascular Therapy for Acute Ischemic Stroke

Start: Nov 2019Est. completion: Dec 202690 patients
N/ARecruiting
NCT04242784MedtronicIMPROVE Stroke Care- Developing and Optimizing Regional Systems of Stroke Care

IMPROVE Stroke Care- Developing and Optimizing Regional Systems of Stroke Care

Start: Jan 2019Est. completion: Apr 202121,646 patients
N/ACompleted

Efficacy of EMF BCI Based Device on Acute Stroke

Start: Sep 2018Est. completion: Mar 202028 patients
N/ATerminated

Michigan Stroke Transitions Trial

Start: Jan 2016Est. completion: Nov 2017320 patients
N/ACompleted
NCT01502748Angeles Therapeuticsendovascular sampling

Endovascular Magnesium Sampling in Acute Stroke

Start: Mar 2012Est. completion: Feb 20132 patients
N/ATerminated

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
2 actively recruiting trials targeting 26,451 patients
19 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.